Inhibikase Therapeutics, Inc.
IKT
$1.94
-$0.15-7.18%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -100.00% | -68.39% | 38.03% | 110.93% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -100.00% | -68.39% | 38.03% | 110.93% |
| Cost of Revenue | 26.38% | -4.75% | -10.20% | 13.84% | 13.16% |
| Gross Profit | -28.84% | 2.44% | 9.09% | -13.55% | -12.14% |
| SG&A Expenses | 69.02% | 5.52% | 6.64% | 5.64% | 8.28% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 40.48% | -1.38% | -4.66% | 10.95% | 11.50% |
| Operating Income | -42.31% | -0.21% | 3.85% | -10.74% | -10.82% |
| Income Before Tax | -44.62% | -2.27% | 3.40% | -7.32% | -5.40% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -44.62% | -2.27% | 3.40% | -7.32% | -5.40% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -44.62% | -2.27% | 3.40% | -7.32% | -5.40% |
| EBIT | -42.31% | -0.21% | 3.85% | -10.74% | -10.82% |
| EBITDA | -43.44% | -0.97% | 3.15% | -47.42% | -125.19% |
| EPS Basic | 33.74% | 26.00% | 29.52% | 25.52% | 22.06% |
| Normalized Basic EPS | 33.75% | 26.00% | 29.52% | 25.52% | 22.06% |
| EPS Diluted | 33.74% | 26.00% | 29.52% | 25.52% | 22.06% |
| Normalized Diluted EPS | 33.75% | 26.00% | 29.52% | 25.52% | 22.06% |
| Average Basic Shares Outstanding | 310.72% | 36.93% | 36.59% | 43.97% | 36.84% |
| Average Diluted Shares Outstanding | 310.72% | 36.93% | 36.59% | 43.97% | 36.84% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |